Top

Published in:

01-03-2011

Combination HIV Prevention: Significance, Challenges, and Opportunities

Authors: Ann E. Kurth, Connie Celum, Jared M. Baeten, Sten H. Vermund, Judith N. Wasserheit

Published in: Current HIV/AIDS Reports | Issue 1/2011

Abstract

No single HIV prevention strategy will be sufficient to control the HIV pandemic. However, a growing number of interventions have shown promise in partially protecting against HIV transmission and acquisition, including knowledge of HIV serostatus, behavioral risk reduction, condoms, male circumcision, needle exchange, treatment of curable sexually transmitted infections, and use of systemic and topical antiretroviral medications by both HIV-infected and uninfected persons. Designing the optimal package of interventions that matches the epidemiologic profile of a target population, delivering that package at the population level, and evaluating safety, acceptability, coverage, and effectiveness, all involve methodological challenges. Nonetheless, there is an unprecedented opportunity to develop “prevention packages” that combine various arrays of evidence-based strategies, tailored to the needs of diverse subgroups and targeted to achieve high coverage for a measurable reduction in population-level HIV transmission. HIV prevention strategies that combine partially effective interventions should be scaled up and evaluated.

WHO, UNAIDS: AIDS epidemic update: December 2009. UNAIDS: Geneva, Switzerland; 2009.

Vermund SH: Rationale for the testing and use of a partially effective HIV vaccine. AIDS Res Hum Retroviruses 1998, 14(Suppl 3):S321–S323.PubMed

Vergidis PI, Falagas ME: Meta-analyses on behavioral interventions to reduce the risk of transmission of HIV. Infect Dis Clin North Am 2009, 23:309–314.CrossRefPubMed

Johnson WD, et al.: Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst Rev 2008, CD001230.

Herbst JH, et al.: A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. J Acquir Immune Defic Syndr 2005, 39:228–241.PubMed

Crepaz N, Marshall KJ, Aupont LW, et al.: The efficacy of HIV/STI behavioral interventions for African American females in the United States: a meta-analysis. Am J Public Health 2009, 99:2069–2078.CrossRefPubMed

Noar SM, Black HG, Pierce LB: Efficacy of computer technology-based HIV prevention interventions: a meta-analysis. AIDS 2009, 23:107–115.CrossRefPubMed

Crepaz N, Horn AK, Rama SM, et al.: The efficacy of behavioral interventions in reducing HIV risk sex behaviors and incident sexually transmitted disease in black and Hispanic sexually transmitted disease clinic patients in the United States: a meta-analytic review. Sex Transm Dis 2007, 34:319–332.PubMed

Vergidis PI, Falagas ME, Hamer DH: Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infect Dis Clin North Am 2009, 23:295–308.CrossRefPubMed

10.

Sturt AS, Dokubo EK, Sint TT: Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010, 3:CD008440.

11.

Siegfried N, et al.: Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009, 2:CD003362.

12.

Chigwedere P, Seage GR, Lee TH, Essex M: Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses 2008, 24:827–837.CrossRefPubMed

13.

Denison JA, O’Reilly KR, Schmid GP, et al.: HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990–2005. AIDS Behav 2008, 12:363–373.CrossRefPubMed

14.

Modjarrad K, Vermund SH: Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 2010, 10:455–463.CrossRefPubMed

15.

Gowing L, et al.: Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008, 2:CD004145.

16.

Buvé A: Track C Epidemiology and Prevention Sciences Rapporteur Summary. In XVIII International AIDS Conference. Vienna: IAS; 2010.

17.

Padian NS, McCoy SI, Balkus JE, Wasserheit JN: Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010, 24:621–635.CrossRefPubMed

18.

•• Piot P, Bartos M, Larson H, et al.: Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008, 372:845–859. This is a clarion call to utilize the available science and to mobilize an HIV prevention constituency that engages affected communities.CrossRefPubMed

19.

Holtgrave DR: Is the elimination of HIV infection within reach in the United States? Lessons from an epidemiologic transmission model. Public Health Rep 2010, 125:372–376.PubMed

20.

UNAIDS Prevention Reference Group definition. From UNAIDS Taxonomy of HIV Prevention Activities. Discussion draft for UNAIDS HIV Prevention Reference Group meeting. March 2–4, 2009.

21.

Wingood GM, DiClemente RJ: The ADAPT-ITT model: a novel method of adapting evidence-based HIV interventions. J Acquir Immune Defic Syndr 2008, 47(Suppl 1):S40–S46.PubMed

22.

Glasgow RE, Vogt TM, Boles SM: Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health 1999, 89:1322–1327.CrossRefPubMed

23.

Methods for Prevention Packages Program (MP3 II) (R01) Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-10-005.html. Accessed August 2010.

24.

Wilson D, Halperin DT: “Know your epidemic, know your response”: a useful approach, if we get it right. Lancet 2008, 372:423–426.CrossRefPubMed

25.

Vandenbruaene M: King Kennard Holmes—chair of the Department of Global Health of The University of Washington. Interviewed by Marc Vandenbruaene. Lancet Infect Dis 2007, 7:516–520.CrossRef

26.

Stoneburner RL, Low-Beer D: Sexual partner reductions explain human immunodeficiency virus declines in Uganda: comparative analyses of HIV and behavioural data in Uganda, Kenya, Malawi, and Zambia. Int J Epidemiol 2004, 33:624.CrossRefPubMed

27.

Blower SM, Gershengorn HB, Grant RM: A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000, 287:650–654.CrossRefPubMed

28.

•• Granich RM, Gilks CF, Dye C, et al.: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48–57. This modeling exercise ignited debate regarding what might be possible for epidemic control if universal HIV testing, treatment, and adherence support were fully accessible.CrossRefPubMed

29.

Dodd PJ, Garnett GP, Hallett TB: Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS 2010, 24:729–735.CrossRefPubMed

30.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209–2220.CrossRefPubMed

31.

Korenromp EL, White RG, Orroth KK, et al.: Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis 2005, 191(Suppl 1):S168–S178.CrossRefPubMed

32.

Allen S, Tice J, Van de Perre P, et al.: Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. BMJ 1992, 304:1605–1609.CrossRefPubMed

33.

Bunnell R, Cherutich P: Universal HIV testing and counselling in Africa. Lancet 2008, 371:2148–2150.CrossRefPubMed

34.

Celum CL, Robinson NJ, Cohen MS: Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005, 191(Suppl 1):S107–S114.CrossRefPubMed

35.

Bassett IV: Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis 2010, 50(Suppl 3):S77–S84.CrossRefPubMed

36.

Khumalo-Sakutukwa G, et al.: Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr 2008, 49:422–431.CrossRefPubMed

37.

Weinhardt LS, et al.: Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997. Am J Public Health 1999, 89:1397–1405.CrossRefPubMed

38.

Sherr L, Lopman B, Kakowa M, et al.: Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. AIDS 2007, 21:851–860.CrossRefPubMed

39.

Corbett EL, Makamure B, Cheung YB, et al.: HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS 2007, 21:483–489.CrossRefPubMed

40.

Huchko MJ, Montandon M, Nguti R, et al.: The association of HIV counseling and testing with HIV risk behaviors in a random population-based survey in Kisumu, Kenya. AIDS Behav 2009 Dec 11 (Epub ahead of print).

41.

WHO and UNICEF: Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector: Progress report 2009. Geneva, Switzerland: WHO: 2009.

42.

Bunnell R, Ekwaru JP, Solberg P, et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006, 20:85–92.CrossRefPubMed

43.

Sullivan P, et al.: Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia. In 5th IAS. Cape Town, SA; 2009.

44.

Donnell D, Baeten JM, Kiarie J, et al.: Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092–2098.CrossRefPubMed

45.

Attia S, Egger M, Müller M, et al.: Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23:1397–1404.CrossRefPubMed

46.

Montaner J, Wood E, Kerr T, et al.: Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in British Columbia, Canada [Paper 88LB]. Presented at the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 16–19, 2010.

47.

Das-Douglas M, Chu, Santos GM, et al.: Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco [Paper #33]. Presented at the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 16–19, 2010.

48.

Kalichman SC, Di Berto G, Eaton L: Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008, 35:55–60.CrossRefPubMed

49.

Amico KR, Harman JJ, Johnson BT: Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 2006, 41:285–297.CrossRefPubMed

50.

Simoni JM, et al.: Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S23–S35.PubMed

51.

WHO: Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents: Geneva, Switzerland: WHO.

52.

Holmes KK, Levine R, Weaver M: Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004, 82:454–461.PubMed

53.

Johnson BT, et al.: Sexual risk reduction for persons living with HIV: research synthesis of randomized controlled trials, 1993 to 2004. J Acquir Immune Defic Syndr 2006, 41:642–650.CrossRefPubMed

54.

Crepaz N, Lyles CM, Wolitski RJ, et al.: Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS 2006, 20:143–157.CrossRefPubMed

55.

Horvath T, et al.: Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev 2009, CD006734.

56.

Des Jarlais DC, Marmor M, Paone D, et al.: HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996, 348:987–991.CrossRefPubMed

57.

Copenhaver MM, Johnson BT, Lee IC, et al.: Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy. J Subst Abuse Treat 2006, 31:163–171.CrossRefPubMed

58.

Malta M, Magnanini MM, Strathdee SA, Bastos FI: Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2008, 14:731–747.CrossRefPubMed

59.

Vermund SH, et al.: Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 2010, 50(Suppl 3):S149–S155.CrossRefPubMed

60.

Zachariah R, Harries AD, Philips M, et al.: Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa? Trans R Soc Trop Med Hyg 2010, 104:387–391.CrossRefPubMed

61.

McCoy SI, Kangwende RA, Padian NS: Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. AIDS Behav 2010, 14:469–482.CrossRefPubMed

62.

•• Karim QA, Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 Jul 19 (Epub ahead of print). This is the first evidence that a topically applied (ART-containing) microbicide can provide protection from HIV among at-risk women: 1% tenofovir gel reduced HIV acquisition by an estimated 39% overall and by 54% in women with high gel adherence.

63.

Mills E, Cooper C, Anema A, Guyatt G: Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med 2008, 9:332–335.CrossRefPubMed

64.

Weiss HA, Hankins CA, Dickson K: Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:669–677.CrossRefPubMed

65.

Grosskurth H, Mosha F, Todd J, et al.: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995, 346:530–536.CrossRefPubMed

66.

Ozler B, et al.: Cash payments can reduce HIV/STIs in Africa—New Bank studies. News release No. 2011//027/HDN, at IAS Meeting. Vienna; July 18, 2010.

67.

Merson M, Padian N, Coates TJ, et al.: Combination HIV prevention. Lancet 2008, 372:1805–1806.CrossRefPubMed

68.

Buse K, Dickinson C, Sidibe M: HIV: know your epidemic, act on its politics. J R Soc Med 2008, 101:572–573.CrossRefPubMed

69.

Grassly NC, Garnett GP, Schwartländer B, et al.: The effectiveness of HIV prevention and the epidemiological context. Bull World Health Organ 2001, 79:1121–1132.PubMed

70.

Hughes JP, Kulich M: Cluster randomized trials for HIV prevention. Curr Opin HIV AIDS 2006, 1:471–475.CrossRefPubMed

71.

DeGruttola V, et al.: Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 2010, 50(Suppl 3):S102–S107.CrossRefPubMed

72.

Anderson RM: Transmission dynamics of sexually transmitted infections. In Sexually Transmitted Diseases, edn 3. Edited by Holmes K, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1998.

73.

Kurth A, Spielberg F: Individual-level risk assessment for STD/HIV infection. In Sexually Transmitted Diseases, edn 4. Edited by Holmes K, Sparling PF, Stamm W, et al. New York: McGraw-Hill; 2008.

Title: Combination HIV Prevention: Significance, Challenges, and Opportunities
Authors: Ann E. Kurth
Connie Celum
Jared M. Baeten
Sten H. Vermund
Judith N. Wasserheit
Publication date: 01-03-2011
Publisher: Current Science Inc.
Published in: Current HIV/AIDS Reports / Issue 1/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-010-0063-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Combination HIV Prevention: Significance, Challenges, and Opportunities

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

The Search for Host Genetic Factors of HIV/AIDS Pathogenesis in the Post-Genome Era: Progress to Date and New Avenues for Discovery

Erratum to: Alterations of the B-Cell Response by HIV-1 Replication

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy

Coreceptors and HIV-1 Pathogenesis

Point-of-Care Testing

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page